title: Effects of nicergoline on the retinal and cortical electrophysiological responses in glaucoma patients: a preliminary open study.
abstract: OBJECTIVE
  The retinal dysfunction and the delayed visual cortex responses shown by patients affected by glaucoma can be objectively assessed by Pattern Electroretinogram (PERG) and Visual Evoked Potentials (VEP) recordings. The present study aims to evaluate the effects of nicergoline on the retinal function and on the visual cortical responses in glaucoma patients.
  
  
  METHODS
  Sixty patients (mean age 44.6+/-3.7) with open angle glaucoma were enrolled. The patients were divided into two groups: NG Group, where 30 patients were treated with nicergoline (Cebran((R)), 2 cps day) for 30 days; and CG Group, where 30 patients were not treated. Simultaneous recordings of PERG and VEP were performed in NG patients at the baseline, at 30 days after treatment with nicergoline (day 30), and at 45 days from the end of the treatment (day 75). PERG and VEP were recorded in CG patients at the baseline and after 30 and 75 days. The visual stimulus for recording PERGs and VEPs was a checkerboard whose elements subtended a visual arc of 60' and 15' with a 70% contrast, and alternated at a frequency of 2 Hz.
  
  
  RESULTS
  At the baseline none of the electrophysiological parameters observed in NG Group patients differed (P>0.05) from those of CG Group patients. At days 30 and 75, in CG Group patients the values of the PERG and VEP parameters were unmodified (P>0.05) with respect to the baseline. In NG Group patients, the 30-day treatment period with nicergoline induced a significant (P<0.01) improvement of the PERG and VEP parameters. At day 75 all the electrophysiological parameters of NG Group did not differ significantly (P>0.05) from those at the baseline.
  
  
  CONCLUSIONS
  Treatment with nicergoline induces an improvement of the retinal function and of the visual cortical responses in patients affected by glaucoma. This effect disappears within 45 days after the suspension of the treatment.
authors.affiliation: Cattedra di Clinica Oculistica, Universita' di Roma 'Tor Vergata, Via Santa Maria Goretti 66, Roma, 00199, Italy,
authors.forename: V
authors.initials: V
authors.lastname: Parisi
authors.forename: G
authors.initials: G
authors.lastname: Colacino
authors.forename: G
authors.initials: G
authors.lastname: Milazzo
authors.forename: A C
authors.initials: AC
authors.lastname: Scuderi
authors.forename: G
authors.initials: G
authors.lastname: Manni
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000328:Adult; D004594:Electrophysiology; D004596:Electroretinography / Q000187:drug effects; D005074:Evoked Potentials, Visual / Q000187:drug effects; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects; D009530:Nicergoline / Q000494:pharmacology*; D012160:Retina / Q000187:drug effects* / Q000503:physiopathology; D014793:Visual Cortex / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D000317:Adrenergic alpha-Antagonists; D009530:Nicergoline